Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947087464> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2947087464 endingPage "e15653" @default.
- W2947087464 startingPage "e15653" @default.
- W2947087464 abstract "e15653 Background: Hepatocellular carcinoma (HCC) is the third cause of cancer related mortality and the primary cause of cancer death. Tumor Treating Fields (TTFields) therapy is an effective anti-neoplastic treatment modality delivered via noninvasive application of low intensity, intermediate frequency, alternating electric fields. Sorafenib, an oral multikinase inhibitor is approved for patients with advanced HCC, yet its survival benefit is still limited. In this work we explored the potential of the use of TTFields alone and in combination with Sorafenib as a treatment for HCC. Methods: HepG2 and Huh-7D12 cells were treated with various TTFields frequencies for 72 hours using the inovitro system. Efficacy of the combined treatment of TTFields and Sorafenib (36-3000 nM) was tested by applying TTFields at the optimal frequency together with various drug concentrations. Cell counts, induction of apoptosis, cell cycle and clonogenic potential were determined. TTFields (1.2 V/cm) and Sorafenib (10 mg/kg) were applied for 6 days to rats injected to the liver with N1S1 HCC cells. Tumor growth was followed using MRI. Results: The optimal TTFields frequency was 150 kHz for both cell lines. TTFields application (1.0 - 1.7 V/cm, 72 hours) at 150 kHz led to 36-40% reduction in cell counts and to additional reduction of over 70% in the clonogenic potential. The combined treatment of TTFields and Sorafenib led to a significant reduction in the number of cells (p < 0.001) as compared to each treatment alone. The averaged tumor volume fold increase of the combination treatment group was significantly lower than the one observed in the: control group, the TTFields group and the Sorafenib group. Conclusions: The results presented in this work demonstrate that TTFields can be an effective treatment against HCC cells and that the combination with Sorafenib may further enhance treatment efficacy." @default.
- W2947087464 created "2019-06-07" @default.
- W2947087464 creator A5005523374 @default.
- W2947087464 creator A5010725636 @default.
- W2947087464 creator A5017815724 @default.
- W2947087464 creator A5021783438 @default.
- W2947087464 creator A5042300902 @default.
- W2947087464 creator A5056907794 @default.
- W2947087464 creator A5057970471 @default.
- W2947087464 creator A5067968042 @default.
- W2947087464 creator A5083247843 @default.
- W2947087464 creator A5089132013 @default.
- W2947087464 creator A5089662345 @default.
- W2947087464 creator A5091378683 @default.
- W2947087464 date "2019-05-20" @default.
- W2947087464 modified "2023-09-23" @default.
- W2947087464 title "The combined treatment of 150 kHz tumor treating fields (TTFields) and sorafenib inhibits hepatocellular carcinoma in vitro and in vivo." @default.
- W2947087464 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15653" @default.
- W2947087464 hasPublicationYear "2019" @default.
- W2947087464 type Work @default.
- W2947087464 sameAs 2947087464 @default.
- W2947087464 citedByCount "1" @default.
- W2947087464 countsByYear W29470874642020 @default.
- W2947087464 crossrefType "journal-article" @default.
- W2947087464 hasAuthorship W2947087464A5005523374 @default.
- W2947087464 hasAuthorship W2947087464A5010725636 @default.
- W2947087464 hasAuthorship W2947087464A5017815724 @default.
- W2947087464 hasAuthorship W2947087464A5021783438 @default.
- W2947087464 hasAuthorship W2947087464A5042300902 @default.
- W2947087464 hasAuthorship W2947087464A5056907794 @default.
- W2947087464 hasAuthorship W2947087464A5057970471 @default.
- W2947087464 hasAuthorship W2947087464A5067968042 @default.
- W2947087464 hasAuthorship W2947087464A5083247843 @default.
- W2947087464 hasAuthorship W2947087464A5089132013 @default.
- W2947087464 hasAuthorship W2947087464A5089662345 @default.
- W2947087464 hasAuthorship W2947087464A5091378683 @default.
- W2947087464 hasConcept C117262875 @default.
- W2947087464 hasConcept C121608353 @default.
- W2947087464 hasConcept C126322002 @default.
- W2947087464 hasConcept C143998085 @default.
- W2947087464 hasConcept C150903083 @default.
- W2947087464 hasConcept C207001950 @default.
- W2947087464 hasConcept C2776231280 @default.
- W2947087464 hasConcept C2778019345 @default.
- W2947087464 hasConcept C2778695046 @default.
- W2947087464 hasConcept C2993652001 @default.
- W2947087464 hasConcept C502942594 @default.
- W2947087464 hasConcept C71924100 @default.
- W2947087464 hasConcept C86803240 @default.
- W2947087464 hasConceptScore W2947087464C117262875 @default.
- W2947087464 hasConceptScore W2947087464C121608353 @default.
- W2947087464 hasConceptScore W2947087464C126322002 @default.
- W2947087464 hasConceptScore W2947087464C143998085 @default.
- W2947087464 hasConceptScore W2947087464C150903083 @default.
- W2947087464 hasConceptScore W2947087464C207001950 @default.
- W2947087464 hasConceptScore W2947087464C2776231280 @default.
- W2947087464 hasConceptScore W2947087464C2778019345 @default.
- W2947087464 hasConceptScore W2947087464C2778695046 @default.
- W2947087464 hasConceptScore W2947087464C2993652001 @default.
- W2947087464 hasConceptScore W2947087464C502942594 @default.
- W2947087464 hasConceptScore W2947087464C71924100 @default.
- W2947087464 hasConceptScore W2947087464C86803240 @default.
- W2947087464 hasIssue "15_suppl" @default.
- W2947087464 hasLocation W29470874641 @default.
- W2947087464 hasOpenAccess W2947087464 @default.
- W2947087464 hasPrimaryLocation W29470874641 @default.
- W2947087464 hasRelatedWork W2013049481 @default.
- W2947087464 hasRelatedWork W2030334275 @default.
- W2947087464 hasRelatedWork W2136191483 @default.
- W2947087464 hasRelatedWork W2314274090 @default.
- W2947087464 hasRelatedWork W2337210229 @default.
- W2947087464 hasRelatedWork W2353665237 @default.
- W2947087464 hasRelatedWork W2601561670 @default.
- W2947087464 hasRelatedWork W2882986831 @default.
- W2947087464 hasRelatedWork W3026091304 @default.
- W2947087464 hasRelatedWork W3165505519 @default.
- W2947087464 hasVolume "37" @default.
- W2947087464 isParatext "false" @default.
- W2947087464 isRetracted "false" @default.
- W2947087464 magId "2947087464" @default.
- W2947087464 workType "article" @default.